Multiple regression analysis showed that the HBV reactivation risk of RA patients treated by LEF was increased by 30% (adjusted coefficient of determination: 0.290) by the basic state of hepatitis B as well as ALT level and SJC28 before treatment (F = 16.559, P < 0.001). This evidence concerns the gene GPT and rheumatoid arthritis.